NUV vs. IBB, HTGC, DNP, ADX, PTY, USA, GSBD, RVT, TY, and GAB
Should you be buying Nuveen Municipal Value Fund stock or one of its competitors? The main competitors of Nuveen Municipal Value Fund include iShares Biotechnology ETF (IBB), Hercules Capital (HTGC), DNP Select Income Fund (DNP), Adams Diversified Equity Fund (ADX), PIMCO Corporate & Income Opportunity Fund (PTY), Liberty All-Star Equity Fund (USA), Goldman Sachs BDC (GSBD), Royce Value Trust (RVT), Tri-Continental (TY), and The Gabelli Equity Trust (GAB). These companies are all part of the "investment offices, not elsewhere classified" industry.
iShares Biotechnology ETF (NASDAQ:IBB) and Nuveen Municipal Value Fund (NYSE:NUV) are both finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, institutional ownership, media sentiment, valuation and risk.
iShares Biotechnology ETF has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Nuveen Municipal Value Fund has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.
In the previous week, iShares Biotechnology ETF and iShares Biotechnology ETF both had 3 articles in the media. iShares Biotechnology ETF's average media sentiment score of 1.56 beat Nuveen Municipal Value Fund's score of 0.80 indicating that Nuveen Municipal Value Fund is being referred to more favorably in the news media.
Given Nuveen Municipal Value Fund's higher probable upside, research analysts plainly believe iShares Biotechnology ETF is more favorable than Nuveen Municipal Value Fund.
iShares Biotechnology ETF pays an annual dividend of $0.41 per share and has a dividend yield of 0.3%. Nuveen Municipal Value Fund pays an annual dividend of $0.34 per share and has a dividend yield of 4.0%. Nuveen Municipal Value Fund has increased its dividend for 2 consecutive years. Nuveen Municipal Value Fund is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
iShares Biotechnology ETF received 28 more outperform votes than Nuveen Municipal Value Fund when rated by MarketBeat users. Likewise, 67.09% of users gave iShares Biotechnology ETF an outperform vote while only 65.83% of users gave Nuveen Municipal Value Fund an outperform vote.
62.5% of iShares Biotechnology ETF shares are owned by institutional investors. Comparatively, 22.5% of Nuveen Municipal Value Fund shares are owned by institutional investors. 1.0% of Nuveen Municipal Value Fund shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
iShares Biotechnology ETF beats Nuveen Municipal Value Fund on 6 of the 10 factors compared between the two stocks.
Get Nuveen Municipal Value Fund News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuveen Municipal Value Fund Competitors List
Related Companies and Tools
